Compare Vanguard Growth Index Fund ETF (VUG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Growth Index Fund ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Growth Index Fund ETF trades at $92 (market cap $384.60B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: Vanguard Growth Index Fund ETF is far larger — about 38× State Street SPDR S&P Biotech ETF's market cap, and Vanguard Growth Index Fund ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Growth Index Fund ETF for 47 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| VUG | XBI | |
|---|---|---|
Market Cap | $384.60B | $10.11B |
Volume | 5,662,307 | 12,903,266 |
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $92.64 | $169.55 |
52-Week Low | $70.00 | $104.99 |
Typical Hold Time | 47 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VUG trades at $92.42, down 0.24% on the day, with a bullish technical outlook supported by moving averages but showing overbought conditions on shorter-term RSI readings. The ETF maintains strong long-term performance credentials with 11-12% average annual returns since 2004, though current concentration in mega-cap tech stocks presents both opportunity and risk. Recent dividend activity shows minimal income generation with a $0.09 distribution scheduled for September 2026.
The growth-focused ETF offers exposure to market-leading companies but faces concentration risk with over 36% in three holdings. Long-term investors benefit from Vanguard's low-cost structure and historical outperformance, though near-term technical indicators suggest potential consolidation. Market sentiment remains positive for buy-and-hold strategies despite recent value stock outperformance in 2026.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
